Document Detail

RAS in Pregnancy and Preeclampsia and Eclampsia.
Jump to Full Text
MedLine Citation:
PMID:  23346385     Owner:  NLM     Status:  PubMed-not-MEDLINE    
Preeclampsia is a common disease of pregnancy characterized by the presence of hypertension and commitment of many organs, including the brain, secondary to generalized endothelial dysfunction. Its etiology is not known precisely, but it involved several factors, highlighting the renin angiotensin system (RAS), which would have an important role in the origin of multisystem involvement. This paper reviews the evidence supporting the involvement of RAS in triggering the disease, in addition to the components of this system that would be involved and how it eventually produces brain engagement.
M Rodriguez; J Moreno; J Hasbun
Related Documents :
21123115 - Experience of freezing human oocytes using sodium-depleted media.
21295515 - Electre tri-c, a multiple criteria decision aiding sorting model applied to assisted re...
24550985 - Updates in reproduction coming from the endocannabinoid system.
18178995 - Holoprosencephaly--a case report.
14714805 - A longitudinal study of distortion product otoacoustic emission ipsilateral suppression...
16247715 - Factors affecting assisted reproductive technology (art) pregnancy rates: a multivariat...
Publication Detail:
Type:  Journal Article     Date:  2012-12-30
Journal Detail:
Title:  International journal of hypertension     Volume:  2012     ISSN:  2090-0392     ISO Abbreviation:  Int J Hypertens     Publication Date:  2012  
Date Detail:
Created Date:  2013-01-24     Completed Date:  2013-01-25     Revised Date:  2013-04-18    
Medline Journal Info:
Nlm Unique ID:  101538881     Medline TA:  Int J Hypertens     Country:  United States    
Other Details:
Languages:  eng     Pagination:  739274     Citation Subset:  -    
Department of Obstetrics and Gynecology, Universidad de Valparaiso, 2341131 Valparaiso, Chile ; Fetal Medicine Unit, Hospital Carlos Van Buren, 2341131 Valparaiso, Chile.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Int J Hypertens
Journal ID (iso-abbrev): Int J Hypertens
Journal ID (publisher-id): IJHT
ISSN: 2090-0384
ISSN: 2090-0392
Publisher: Hindawi Publishing Corporation
Article Information
Download PDF
Copyright © 2012 M. Rodriguez et al.
Received Day: 22 Month: 11 Year: 2012
Accepted Day: 14 Month: 12 Year: 2012
Print publication date: Year: 2012
Electronic publication date: Day: 30 Month: 12 Year: 2012
Volume: 2012E-location ID: 739274
PubMed Id: 23346385
ID: 3546487
DOI: 10.1155/2012/739274

RAS in Pregnancy and Preeclampsia and Eclampsia
M. Rodriguez12
J. Moreno12*
J. Hasbun3
1Department of Obstetrics and Gynecology, Universidad de Valparaiso, 2341131 Valparaiso, Chile
2Fetal Medicine Unit, Hospital Carlos Van Buren, 2341131 Valparaiso, Chile
3Fetal Medicine Unit, Hospital Clinico Universidad de Chile, 8380456 Santiago, Chile
Correspondence: *J. Moreno:
[other] Academic Editor: Marc de Gasparo

1. Introduction

Preeclampsia is a major complication of pregnancy and corresponds to a major cause of both maternal and fetal morbidity and mortality [13]. It is a condition that produces a compromise of many organs, including the brain causing seizures, a condition known as eclampsia [4, 5]. The pathophysiology is not well understood, but it involves different factors, such as genetic, immunological, and inflammatory [6, 7]. In recent years there is a series of studies linking the renin angiotensin system (RAS) with preeclampsia [810], in the sense that the alteration of this system would be involved in the pathogenesis of this disease, as this could trigger the different characteristics in this pathology, including brain involvement.

2. RAS in Normal Pregnancy

RAS is a system that functions as an important regulator of blood pressure, electrolyte balance, and fluid homeostasis [11]. This system comprises the inactive peptide angiotensinogen, which is converted to angiotensin I and then the active peptide angiotensin II (Ang II) through the action of renin and angiotensin-converting enzyme (ACE) [12]. Ang II exerts its action primarily through the AT1 receptor, located widely in different tissues, including the syncytiotrophoblast [10].

During pregnancy usually occurs overexpression of many components of the RAS, both in the blood and tissues. There is an increase in plasma renin mainly by extrarenal production [13]. There is also a higher-level production of angiotensinogen liver secondary to increased circulating estrogens. ACE is the only component that has been shown to decrease during normal pregnancy, but equally there is a higher plasma concentration of Ang II [8, 13].

There is an upregulation of RAS components during normal pregnancy, but there is also a decrease in sensitivity to Ang II, whereby these women are resistant to the pressor effect of this molecule, requiring twice Ang II by intravenous infusion compared with nonpregnant women to achieve a similarly vasomotor response [14].

It is thought that this might be related to the monomer structure of AT1 during uncomplicated pregnancies, unlike the heterodimeric structure observed in terms of sensitivity to Ang II [15]. In addition, estrogens produce a shift in the formation of angiotensin peptides, reducing the formation of Ang II and increasing the production of Ang-(1–7), which has a vasodilator role [16].

Furthermore, in addition to a systemic RAS, RAS also exists in uteroplacental territory [13]. This unit consists of a placental portion, corresponding to fetal tissue, and a decidual, which is of maternal origin, and in both all components of the RAS are secreted. Therefore, there are 2 RAS systems: placental and decidual. The latter could be related to the pregnancy-associated vascular remodeling of the spiral arteries [17].

3. Pathophysiology of Preeclampsia: Role of RAS

Preeclampsia corresponds to a multisystem disorder characterized by increased peripheral vascular resistance, increased platelet aggregation, and systemic endothelial dysfunction [18]. Corresponds to a multifactorial disease, involving genetic and environmental components, a defective extravillous trophoblast invasion, an impaired immune tolerance between maternal, fetal and placental tissues and maternal inflammatory disorders [19, 20]. Clinically it is characterized by the presence of hypertension and proteinuria from the 2nd half of pregnancy, and the only effective treatment is the termination of pregnancy [21].

From a physiological point of view, preeclampsia is defined as a disease of two stages [22]. The first is the placental stage that occurs during the first 20 weeks of gestation. In this, the phenomena of remodeling of the vascular walls of the spiral arteries do not develop properly, resulting in abnormal placentation, thus prompting ischemic placenta [23]. The second stage occurs during the second half of pregnancy and is known as the systemic stage. This is the clinical stage of preeclampsia, in which there is an exaggerated maternal systemic inflammatory response and endothelial dysfunction as a central element [2426]. Between these two stages are some mediators, which are understood as molecules released by the placenta and are capable of transmitting this placental damage and translate into a systemic involvement. Mediators most studied are oxidative stress, microfragments of syncytiotrophoblast (STBM), and antiangiogenic proteins [27].

There is a considerable amount of evidence supporting the role of angiogenic factors in triggering preeclampsia, and these are the tyrosine-like soluble factor (sFlt-1) and soluble endoglin (s-Eng) [28, 29]. These molecules bind to angiogenic proteins such as VEGF and prevent them from joining their membrane receptors on endothelial cells, leading to endothelial dysfunction [30]. It was observed that these factors are elevated about 6–8 weeks before the start of the clinical picture of preeclampsia, and their plasma concentrations are related to the severity of the disease [31, 32]. In animal models it has been found that inoculation of these can produce hypertension, proteinuria, and hepatic involvement, symptoms characteristic of preeclampsia [33, 34]. It is also observed that hypoxia causes increased secretion of these factors [35].

In patients with preeclampsia, dysregulation has been observed in the RAS compared to healthy pregnancies. The levels of renin, Ang I, and Ang II are lower than in uncomplicated pregnancies [36]. Despite this decrease in the expression of RAS components, in patients suffering from preeclampsia increased sensitivity to Ang II exists, showing an exaggerated pressor response to Ang II.

4. AT1 Receptors Autoantibodies in Preeclampsia

In recent years there is a wealth of evidence supporting the AT1 autoantibodies (AT1-AA) in the pathogenesis of preeclampsia. These correspond to IgG autoantibodies that bind to a seven-amino acid sequence present on the second extracellular loop of the AT1 receptor [37, 38]. They are present in the plasma of patients with preeclampsia and are able to increase the beating rate of the cultured cardiomyocytes [39]. Many research papers show that these autoantibodies are elevated in patients with preeclampsia, but not in uncomplicated pregnancies.

In vitro and in vivo studies have determined its role in triggering preeclampsia. These antibodies bind to the AT1 receptors of different cell groups, triggering its pathological action [40]. It has been observed that in human trophoblast cells AT1-AA substances induce the generation of reactive oxygen species (ROS) intracellularly through NDPH oxidase activation [41]. In addition, these same cells stimulate the release of PAI-1, resulting in a decreased trophoblast invasiveness [42, 43], generating a defect of placentation. This increase in PAI-1 is also observed in mesangial cells, which can produce a decrease in extracellular matrix degradation and increased subendothelial fibrin deposition thereby determining renal damage leading to proteinuria and a decreased glomerular filtration rate [44]. It has also been observed that AT1-AA binds to endothelial and vascular cells, causing endothelial damage and vasoconstriction [45, 46].

All these actions could explain endothelial dysfunction, increased peripheral vascular resistance, and impaired coagulation system observed in preeclampsia.

In animal models it has been observed that the inoculation of AT1-AA from patients with preeclampsia is capable of reproducing the characteristics of the disease [47, 48]. Reports in rats showed that surgically induced placental ischemia may cause increased levels of AT1-AA and trigger hypertension and proteinuria [4951]. It was also observed that these autoantibodies stimulate the release of sFlt-1 and s-eng by the placenta, key proteins in triggering endothelial dysfunction [52, 53].

In the same way pregnant human studies show that placental perfusion abnormality, evaluated with Doppler ultrasound of the uterine arteries, is associated with increased plasma concentrations of AT1-AA before the onset of the disease and that plasmatic levels of these autoantibodies correlate with the severity [54]. The concentration of these autoantibodies is higher in cases of severe preeclampsia, also having a linear correlation with proteinuria and hypertension. This is further confirmed by the fact that in milder cases, as moderate preeclampsia and gestational hypertension, levels of AT1-AA are higher than in normotensive pregnancies, but lower than in severe preeclampsia. Therefore, AT1-AA would be a key element in the pathogenesis of preeclampsia and modulate the secretion of important factors responsible for the pathophysiology [55].

5. Eclampsia: Loss of Autoregulation of Cerebral Blood Flow and Possible Role of RAS

One of the most serious complications of preeclampsia is eclampsia, which corresponds to the presence of seizures in the context of a patient with hypertension and proteinuria [5, 56]. However, currently the eclampsia is being seen as a manifestation of a much larger entity than pregnancy, known as posterior reversible encephalopathy (PRES), which is produced by other conditions such as hypertensive encephalopathy or use of immunosuppressive drugs. In these cases there is a characteristic increase in blood pressure and/or alteration of endothelial permeability [5760].

The PRES is characterized by the presence of well-defined signs and symptoms associated with the presence of specific neuroimaging. Among the symptoms are headache, nausea, vomiting, visual disturbances, and seizures [61, 62]. Diagnosis is by observation of symmetrical hyperintense lesions and bilateral parietooccipital level on MRI, suggestive of vasogenic edema [63].

The exact pathophysiology of PRES is not known with certainty, but is thought to be due to alterations of the vasculature and cerebral perfusion [64]. With the increase in blood pressure, brain responds with its vasculature vasoconstriction, which determines an increase of cerebral perfusion pressure (CPP). As this CPP remains persistently high, it will produce a pressure transmission to the distal small cerebral vessels, causing endothelial damage and muscle dysfunction of cerebral vascular territory [65, 66]. This phenomenon is known as barotrauma, corresponding to forced dilation of arterioles and distal opening of endothelial tight junctions, determining a disruption of the blood-brain barrier (BBB), which leads to increased permeability of this, resulting in a vasogenic edema [67].

However, not all cases of PRES relate to alterations in arterial pressure. One study shows that 16% of cases of eclampsia occur in normotensive patients, and only 13% of cases were associated with severe hypertension [68, 69]. Therefore, the loss of autoregulation of cerebral perfusion secondary to hypertension does not explain all cases of PRES, so that alteration of endothelial permeability by disruption of the BBB ought to play an important role [67]. A recent study shows that preeclampsia altered BBB permeability independently of blood pressure. In this report it is determined that plasma from patients with preeclampsia significantly increases the permeability of the BBB, compared to plasma from patients with normal pregnancies [70]. These findings support the concept of the pathophysiology of PRES that is determined by hemodynamic factors and factors altering endothelial function.

Various reports have identified the involvement of RAS in the blood-brain barrier disruption in other medical conditions [71]. Therefore, the presence of AT1-AA in patients with preeclampsia could play a key role in triggering PRES. It is shown that these autoantibodies produced an increase in peripheral vascular resistance and hypertension, which leads to a systemic endothelial dysfunction via ROS secretion and antiangiogenic proteins [37, 40], so directly involved in the conditions that can trigger PRES.

6. Management of Preeclampsia and Eclampsia Prevention

Currently, the only effective treatment for preeclampsia is the termination of pregnancy, which in very early pregnancies may not be the best alternative, as this results in increased perinatal morbidity and mortality secondary to prematurity [72]. Therefore, it is important to seek management strategies from the physiological point of view, and in that sense, the management of RAS alteration appears to be a logical choice, given the strong evidence about an excessive AT1 receptor activation during preeclampsia.

Regarding eclampsia, the drug of choice for prevention and management is magnesium sulfate. This drug reduces the risk of seizures in patients with severe preeclampsia [73]. Its mechanism of action is not entirely clear, but it has been shown to be capable of reducing the CPP [74]. However, it should be administered intravenously and usually for 48 hrs, in patient hospitalized and only for short periods of time.

Many studies determined that the addition of losartan (AT1 receptors blocker) or neutralizing antibodies of the AT1-AA (7-amino acid peptide epitope or 7-aa) blocks the effect of AT1-AA, further confirming that the action of these antibodies is through activation of AT1 receptors (z). Animal studies with surgically induced placental ischemia demonstrate that the addition of these compounds significantly reduces arterial pressure [49], but this effect was not seen with ACE inhibitors [75]. In another report, AT1-AA purified from pregnant women was injected in mice. They triggered hypertension and proteinuria, were significantly reduced or abolished when administered losartan or 7-aa [47]. Adoptive transfer studies in pregnant mice have demonstrated that release of antiangiogenic factors and proinflammatory cytokines resulting from autoantibody-mediated receptor activation is blocked by the addition of 7-aa or AT1 receptor antagonist [10, 37].

The main problem with AT1 receptors blockers is that they increase the risk of fetal malformations, such as oligohydramnios, pulmonary hypoplasia, transient renal failure, preterm delivery, and Potter syndrome [7678], so its use during pregnancy should be avoided. However, AT1 receptors blockers can be used postpartum, and considering that currently about 30% of eclampsia occur in postpartum [56, 79] and that AT1-AA levels can remain high for a long time [80], AT1 receptors blockers become an interesting strategy for the management of hypertension during the postpartum period and to decrease the incidence of eclampsia, as well as controlling blood pressure; they block the action of endothelial AT1-AA, which is still present in the postpartum period.

Neutralizing antibodies 7-aa have the advantage of not inhibiting the AT1 receptor; they only block the AT1-AA, without changing completely the action of Ang II. Therefore, it seems a useful strategy for the management of preeclampsia. However, we must await the development of further studies to determine its safety during pregnancy.

7. Discussion

During preeclampsia there is an alteration of the RAS. The presence of AT1-AA determines triggering a series of actions in tissues and organs that would result in an increase in peripheral vascular resistance, altered coagulation, renal impairment, and systemic endothelial dysfunction. These alterations can generate the commitment of many organs, including the brain, producing a PRES.

Blocking the action of these autoantibodies using losartan or 7-aa substantially decreases the damage caused by AT1-AA, creating an opportunity for the management and prevention of complications of preeclampsia.

1. Sibai B,Dekker G,Kupferminc M. Pre-eclampsiaThe LancetYear: 200536594617857992-s2.0-14644412849
2. Duley L. Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America and the CaribbeanBritish Journal of Obstetrics and GynaecologyYear: 19929975475532-s2.0-00266333691525093
3. Duley L. The global impact of pre-eclampsia and eclampsiaSeminars in PerinatologyYear: 20093331301372-s2.0-6564912569019464502
4. Norwitz ER,Hsu CD,Repke JT. Acute complications of preeclampsiaClinical Obstetrics and GynecologyYear: 20024523083292-s2.0-003627770312048392
5. Zeeman GG. Neurologic complications of pre-eclampsiaSeminars in PerinatologyYear: 20093331661722-s2.0-6564910452719464507
6. Roberts JM,Cooper DW. Pathogenesis and genetics of pre-eclampsiaThe LancetYear: 2001357924953562-s2.0-0035814640
7. James JL,Whitley GS,Cartwright JE. Pre-eclampsia: fitting together the placental, immune and cardiovascular piecesJournal of PathologyYear: 201022143633782-s2.0-7795549922420593492
8. Shah DM. Role of the renin-angiotensin system in the pathogenesis of preeclampsiaAmerican Journal of PhysiologyYear: 20052884F614F6252-s2.0-1504434824615753325
9. Irani RA,Xia Y. The functional role of the renin-angiotensin system in pregnancy and preeclampsiaPlacentaYear: 20082997637712-s2.0-5004912884118687466
10. Irani RA,Xia Y. Renin angiotensin signaling in normal pregnancy and preeclampsiaSeminars in NephrologyYear: 201131147582-s2.0-7875168473421266264
11. Shah DM. The role of RAS in the pathogenesis of preeclampsiaCurrent Hypertension ReportsYear: 20058214415216672148
12. Welches WR,Brosnihan KB,Ferrario CM. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11Life SciencesYear: 19935218146114802-s2.0-00274068618387132
13. Anton L,Brosnihan KB. Systemic and uteroplacental renin-angiotensin system in normal and pre-eclamptic pregnanciesTherapeutic Advances in Cardiovascular DiseaseYear: 2008253493622-s2.0-6564914228519124433
14. Abdul-Karim R,Assali NS. Pressor response to angiotensin in pregnant and non-pregnant womenAmerican Journal of Obstetrics and GynecologyYear: 19618224625113680954
15. AbdAlla S,Lother H,El Massiery A,Quitterer U. Increased AT1 receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsivenessNature MedicineYear: 200179100310092-s2.0-0034785580
16. Brosnihan KB,Neves LAA,Anton L,Joyner J,Valdes G,Merrill DC. Enhanced expression of Ang-(1–7) during pregnancyBrazilian Journal of Medical and Biological ResearchYear: 2004378125512622-s2.0-444422269015273828
17. Morgan T,Craven C,Lalouel JM,Ward K. Angiotensinogen Thr235 variant is associated with abnormal physiologic change of the uterine spiral arteries in first-trimester deciduaAmerican Journal of Obstetrics and GynecologyYear: 19991801 I951022-s2.0-00330244759914585
18. Poston L. Endothelial dysfunction in pre-eclampsiaPharmacological ReportsYear: 20065869742-s2.0-3534883709217332674
19. Redman CWG,Sargent IL. Placental stress and pre-eclampsia: a revised viewPlacentaYear: 200930S38S422-s2.0-6024910303219138798
20. Kaufmann P,Black S,Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsiaBiology of ReproductionYear: 2003691172-s2.0-003811315512620937
21. ACOG Committee on Obstetric PracticeACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American college of obstetricians and gynecologistsInternational Journal of Gynecology and ObstetricsYear: 2002771677512094777
22. Redman CW,Sargent IL. Latest advances in understanding preeclampsiaScienceYear: 20053085728159215942-s2.0-2044440913515947178
23. Chaddha V,Viero S,Huppertz B,Kingdom J. Developmental biology of the placenta and the origins of placental insufficiencySeminars in Fetal and Neonatal MedicineYear: 2004953573692-s2.0-1274425478015691771
24. Redman CWG,Sargent IL. Pre-eclampsia, the placenta and the maternal systemic inflammatory response—a reviewPlacentaYear: 200324S21S272-s2.0-014183813312842410
25. Bernardi F,Guolo F,Bortolin T,Petronilho F,Dal-Pizzol F. Oxidative stress and inflammatory markers in normal pregnancy and preeclampsiaJournal of Obstetrics and Gynaecology ResearchYear: 20083469489512-s2.0-5564909794319012691
26. Granger JP,Alexander BT,Llinas MT,Bennett WA,Khalil RA. Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunctionMicrocirculationYear: 2002931471602-s2.0-003665420712080413
27. Levine RJ,Karumanchi SA. Circulating angiogenic factors in preeclampsiaClinical Obstetrics and GynecologyYear: 20054823723862-s2.0-1804437064315805796
28. Maynard S,Epstein FH,Karumanchi SA. Preeclampsia and angiogenic imbalanceAnnual Review of MedicineYear: 20085961782-s2.0-39649101109
29. Wang A,Rana S,Karumanchi SA. Preeclampsia: the role of angiogenic factors in its pathogenesisPhysiologyYear: 20092431471582-s2.0-6764922764719509125
30. Kendall RL,Thomas KA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptorProceedings of the National Academy of Sciences of the United States of AmericaYear: 1993902210705107092-s2.0-00274213338248162
31. Levine RJ,Maynard SE,Qian C,et al. Circulating angiogenic factors and the risk of preeclampsiaThe New England Journal of MedicineYear: 200435076726832-s2.0-1074422719914764923
32. Levine RJ,Lam C,Qian C,et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsiaThe New England Journal of MedicineYear: 20063551099210052-s2.0-3374842166016957146
33. Maynard SE,Min JY,Merchan J,et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction hypertension, and proteinuria in preeclampsiaJournal of Clinical InvestigationYear: 200311156496582-s2.0-003737300612618519
34. Venkatesha S,Toporsian M,Lam C,et al. Soluble endoglin contributes to the pathogenesis of preeclampsiaNature MedicineYear: 20061266426492-s2.0-33744985816
35. Makris A,Thornton C,Thompson J,et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1Kidney InternationalYear: 200771109779842-s2.0-3424834133217377512
36. Herse F,Staff AC,Hering L,Müller DN,Luft FC,Dechend R. AT1-receptor autoantibodies and uteroplacental RAS in pregnancy and pre-eclampsiaJournal of Molecular MedicineYear: 20088666977032-s2.0-4344913406418398593
37. Xia Y,Cissy CZ,Ramin SM,Kellems RE. Angiotensin receptors, autoimmunity, and preeclampsiaJournal of ImmunologyYear: 20071796339133952-s2.0-35748966703
38. Xia Y,Kellems R. Receptor-activating autoantibodiesand disease: preeclampsia and bevondExpert Review of Clinical ImmunologyYear: 20117565967421895478
39. Wallukat G,Homuth V,Fischer T,et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptorJournal of Clinical InvestigationYear: 199910379459522-s2.0-003292492210194466
40. LaMarca B,Wallace K,Granger J. Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsiaCurrent Opinion in PharmacologyYear: 201111217517921317038
41. Dechend R,Viedt C,Müller DN,et al. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidaseCirculationYear: 200310712163216392-s2.0-003738401612668498
42. Xia Y,Wen HY,Kellems RE. Angiotensin II inhibits human trophoblast invasion through AT1 receptor activationThe Journal of Biological ChemistryYear: 20022772724601246082-s2.0-003702532011983698
43. Xia Y,Wen H,Bobst S,Day MC,Kellems RE. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cellsJournal of the Society for Gynecologic InvestigationYear: 200310282932-s2.0-003731709012593997
44. Bobst SM,Day MC,Gilstrap LC,Xia Y,Kellems RE. Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretionAmerican Journal of HypertensionYear: 20051833303362-s2.0-1574438294315797649
45. Dechend R,Homuth V,Wallukat G,et al. AT1 receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factorCirculationYear: 200010120238223872-s2.0-003470499910821814
46. Yang X,Wang F,Chang H,et al. Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activationJournal of HypertensionYear: 2008268162916352-s2.0-5154908350418622242
47. Zhou CC,Zhang Y,Irani RA,et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant miceNature MedicineYear: 200814855862
48. LaMarca B,Parrish M,Ray LF,et al. Hypertension in response to autoantibodies to the angiotensin II type i receptor (AT1-AA) in pregnant rats: role of endothelin-1HypertensionYear: 20095449059092-s2.0-7034968042119704104
49. LaMarca B,Wallukat G,Llinas M,Herse F,Dechend R,Granger JP. Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor α in pregnant ratsHypertensionYear: 2008526116811722-s2.0-5744910234518852381
50. Granger JP,LaMarca BB,Cockrell K,et al. Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemiaMethods in Molecular MedicineYear: 20061223833922-s2.0-3364591703516511995
51. LaMarca BB,Bennett WA,Alexander B,et al. Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-αHypertensionYear: 2005464102210252-s2.0-3364464221416144982
52. Zhou CC,Ahmad S,Mi T,et al. Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signalingHypertensionYear: 2008514101010192-s2.0-4084910512818259044
53. Zhou CC,Irani RA,Zhang Y,et al. Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-α induction contributes to increased soluble endoglin production in preeclampsiaCirculationYear: 201012134364442-s2.0-7664911807020065159
54. Walther T,Wallukat G,Jank A,et al. Angiotensin II type 1 receptor agonistic antibodies reflect fundamental alterations in the uteroplacental vasculatureHypertensionYear: 2005466127512792-s2.0-3194445145716260641
55. Siddiqui AH,Irani RA,Blackwell SC,Ramin SM,Kellems RE,Xia Y. Angiotensin receptor agonistic autoantibody is highly prevalent in preeclampsia: correlation with disease severityHypertensionYear: 20105523863932-s2.0-7494910657419996068
56. Sibai BM. Diagnosis, prevention, and management of eclampsiaObstetrics and GynecologyYear: 200510524024102-s2.0-1354427788515684172
57. Hinchey J,Chaves C,Appignani B,et al. A reversible posterior leukoencephalopathy syndromeThe New England Journal of MedicineYear: 199633484945002-s2.0-133442846358559202
58. Tollemar J,Ringden O,Ericzon BG,et al. Cyclosporine-associated central nervous system toxicityThe New England Journal of MedicineYear: 1988318127887892-s2.0-00238497273347234
59. Sloane JP,Lwin KY,Gore ME,et al. Disturbannce of blood-brain barrier after bone-marrow transplantationThe LancetYear: 1985284492802812-s2.0-0021892717
60. Verbeke M,van de Voorde J,de Ridder L,Lameire N. Functional analysis of vascular dysfunction in cyclosporin treated ratsCardiovascular ResearchYear: 1994288115211562-s2.0-00280304667954616
61. Lee VH,Wijdicks EFM,Manno EM,Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndromeArchives of NeurologyYear: 20086522052102-s2.0-3904913981518268188
62. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical featuresAmerican Journal of NeuroradiologyYear: 2008296103610422-s2.0-4674915587618356474
63. Bartynski WS,Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndromeAmerican Journal of NeuroradiologyYear: 2007287132013272-s2.0-3454816281417698535
64. Oehm E,Reinhard M,Keck C,Els T,Spreer J,Hetzel A. Impaired dynamic cerebral autoregulation in eclampsiaUltrasound in Obstetrics and GynecologyYear: 20032243953982-s2.0-014210629014528476
65. Oehm E,Hetzel A,Els T,et al. Cerebral hemodynamics and autoregulation in reversible posterior leukoencephalopathy syndrome caused by pre-/eclampsiaCerebrovascular DiseasesYear: 2006222-32042082-s2.0-3374632928216766873
66. Belfort MA,Varner MW,Dizon-Townson DS,Grunewald C,Nisell H. Cerebral perfusion pressure, and not cerebral blood flow, may be the critical determinant of intracranial injury in preeclampsia: a new hypothesisAmerican Journal of Obstetrics and GynecologyYear: 200218736266342-s2.0-003673899712237639
67. Cipolla MJ. Cerebrovascular function in pregnancy and eclampsiaHypertensionYear: 200750114242-s2.0-3425085413017548723
68. Mattar F,Sabai BM. Eclampsia. VIII. Risk factors for maternal mortalityAmerican Journal of Obstetrics and GynecologyYear: 2000182230731210694329
69. Sibai BM. Eclampsia. VI. Maternal-perinatal outcome in 254 ocnsecutive casesAmerican Journal of Obstetrics and GynecologyYear: 19901633104910552-s2.0-00250017472403130
70. Amburgey O,Chapman AC,May V,Bernstein IM,Cipolla MJ. Plasma from preeclamptic women increases blood-brain barrier permeability: role of vascular endothelial growth factor signalingHypertensionYear: 2010565100310082-s2.0-7814926812820855653
71. Pelisch N,Hosomi N,Ueno M,et al. Blockade of AT1 receptors protects the blood-brain barrier and improves cognition in dahl salt-sensitive hypertensive ratsAmerican Journal of HypertensionYear: 20112433623682-s2.0-7995167753221164491
72. Sibai BM. Diagnosis and management of gestational hypertension and preeclampsiaObstetrics and GynecologyYear: 200310211811922-s2.0-003770788912850627
73. Altman D,Carroli G,Duley L,et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie trial: a randomised placebo-controlled trialThe LancetYear: 20023599321187718902-s2.0-0036606736
74. Belfort M,Allred J,Dildy G. Magnesium sulfate decreases cerebral perfusion pressure in preeclampsiaHypertension in PregnancyYear: 20082743153272-s2.0-5604909528619003633
75. Alexander BT,Cockrell K,Cline FD,Llinas MT,Sedeek M,Granger JP. Effect of angiotensin II synthesis blockade on the hypertensive response to chronic reductions in uterine perfusion pressure in pregnant ratsHypertensionYear: 20013837427452-s2.0-003546311411566968
76. Roger N,Popovic I,Madelenat P,Mahieu-Caputo D. Fetal toxicity of angiotensin-II-receptor inhibitors. Case reportGynecologie Obstetrique FertiliteYear: 20073565565602-s2.0-34250310864
77. Bos-Thompson MA,Hillarire-Buys D,Muller F,et al. Fetal toxic effects of angiotensin II receptor antagonists: case report and follow-up after birthThe Annals of PharmacotherapyYear: 200539115716115590878
78. Kato K,Okuda M,Ishikawa H,Takahashi T,Hirahara F. Oligohydramnios and pulmonary hypoplasia: a case in which involvement of an angiotensin II receptor antagonist was suspectedJournal of Obstetrics and Gynaecology ResearchYear: 20083422422462-s2.0-4214916352018412789
79. Hubel CA,Wallukat G,Wolf M,et al. Agonistic angiotensin II type 1 receptor autoantibodies in postpartum women with a history of preeclampsiaHypertensionYear: 20074936126172-s2.0-3384706549917210828
80. Chames MC,Livingston JC,Invster TS,et al. Late postpartum eclampsia: a preventable disease?American Journal of Obstetrics and GynecologyYear: 200218661174117712066093

Article Categories:
  • Review Article

Previous Document:  Methanogenic Community Dynamics during Anaerobic Utilization of Agricultural Wastes.
Next Document:  Theranostic implications of nanotechnology in multiple sclerosis: a future perspective.